A Phase Two Study of ZD6474 [vandetanib] in Patients With Relapsed Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2016
At a glance
- Drugs Vandetanib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 11 Sep 2009 Actual end date (8 Apr 2004) added as reported by National Cancer Institute of Canada.
- 17 Oct 2006 Status change
- 20 Sep 2005 New trial record.